New Immunotherapy Candidate receives FDA Fast Track Designation – Labiotech.eu (blog)
|
New Immunotherapy Candidate receives FDA Fast Track Designation
Labiotech.eu (blog) Cell Medica’s Orphan Drug CMD-003 has received fast track designation by the FDA to advance immunotherapy of patients with Epstein Bar Virus (EBV)-associated malignancies. The FDA’s fast track designation has been designed to facilitate and accelerate … Cell Medica: Lead Cancer Immunotherapy Candidate Receives FDA …Business Wire (press release) |
Forbes |
How Much Is a CRISPR Patent License Worth?
Forbes Last Wednesday, the Patent Trial and Appeal Board (PTAB) ruled in favor of the Broad Institute in the most monumental biotech patent dispute in decades: a patent “interference” trial over foundational patents covering CRISPR-Cas9, a revolutionary … |